A pharmacoeconomic model has been developed to estimate the potential impact of the IMBG in clinical outcomes and cost savings in the follow-up period of patients with RT. Cost savings are expected to happen :
- In patients with high immunological risk that show low-sensitivity patterns to the IS they are taking . They will benefit from a change in IS regimen to decrease the graft rejection risk.
- In patients with good clinical evolution and a high sensitivity pattern their IS regimen. They will benefit from dose adjustments/reductions to decrease the risk of IS adverse reactions like metabolic disorders, opportunistic infections or malignancies.
The pharmacoeconomic model was based in the following assumptions:
- Probabilistic second-order Monte Carlo simulation
- Hypothetical cohort of 1,000 patients 1 year after renal transplantation
- Spanish NHS Perspective
- Time horizon of 5 years
- Only Direct Costs are included*
- All model assumptions were validated by a Spanish clinical experts’ panel
Direct costs associated with graft failure (dialysis, retransplantation), IS therapy, and Adverse Events management were obtained from Spanish sources
Key results of the analysis were
- The use of the the IMBG would entail a potential risk reduction of graft failure with a saving of costs per HR patient in 5 years of € 20,279 (95% CI € 17,512-23,105) and a 100% saving probability
- The use of the IMBG would entail an expected reduction in the AE rate that would generate savings per non-HR patient in 5 years of € 3,328 (95% CI € 451-7,957) and a 99.5% saving probability
This pharmacoeconomic model will be presented in the next congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2019)
This model can be easily adapted for different countries and health care systems as long as data of transplantation maintenance costs are available